0001564590-22-022768.txt : 20220608 0001564590-22-022768.hdr.sgml : 20220608 20220608161122 ACCESSION NUMBER: 0001564590-22-022768 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 12 CONFORMED PERIOD OF REPORT: 20220607 ITEM INFORMATION: Other Events FILED AS OF DATE: 20220608 DATE AS OF CHANGE: 20220608 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Evoke Pharma Inc CENTRAL INDEX KEY: 0001403708 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 208447886 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36075 FILM NUMBER: 221003640 BUSINESS ADDRESS: STREET 1: 420 STEVENS AVENUE STREET 2: SUITE 370 CITY: SOLANA BEACH STATE: CA ZIP: 92075 BUSINESS PHONE: 858-345-1494 MAIL ADDRESS: STREET 1: 420 STEVENS AVENUE STREET 2: SUITE 370 CITY: SOLANA BEACH STATE: CA ZIP: 92075 8-K 1 evok-8k_20220607.htm 8-K evok-8k_20220607.htm
false 0001403708 0001403708 2022-06-07 2022-06-07

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):  June 7, 2022

 

EVOKE PHARMA, INC.

(Exact Name of Registrant as Specified in its Charter)

 

 

Delaware

 

001-36075

 

20-8447886

(State or Other Jurisdiction

of Incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

 

 

420 Stevens Avenue, Suite 370

Solana Beach, California

 

92075

(Address of Principal Executive Offices)

 

(Zip Code)

Registrant’s telephone number, including area code: (858) 345-1494

(Former Name or Former Address, if Changed Since Last Report.)

 

Securities registered pursuant to Section 12(b) of the Exchange Act

 

 

 

Title of each class

Trading symbol

Name of each exchange on which registered

Common Stock,
par value $0.0001 per share

EVOK

The Nasdaq Capital Market

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

 

 

 

 


 

 

Item 8.01     Other Events.  

On June 7, 2022, Evoke Pharma, Inc. (the “Company”) received written notice from the Listing Qualifications Department of  the Nasdaq Stock Market (“Nasdaq”) stating that the Company has regained compliance with the Nasdaq minimum bid price continued listing requirement and the matter is now closed.

 

The Company was previously notified by Nasdaq on December 29, 2021 that it was not in compliance with the minimum bid price requirement because its common stock had failed to maintain a minimum bid price of $1.00 or more for 30 consecutive business days. To regain compliance, the Company’s common stock was required to maintain a minimum closing bid price of $1.00 or more for at least 10 consecutive trading days, which was achieved on June 6, 2022 subsequent to the Company’s 1-for-12 reverse stock split.

 

Safe Harbor Statement

Evoke cautions you that statements included in this report that are not a description of historical facts are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or the negatives of these terms or other similar expressions. These statements are based on the company’s current beliefs and expectations. These forward-looking statements include statements regarding: whether Evoke can continue to demonstrate compliance with the Nasdaq’s continued listing rules, including with respect to the minimum bid price requirement. The inclusion of forward-looking statements should not be regarded as a representation by Evoke that any of its plans will be achieved. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in Evoke’s business, including, without limitation: Evoke’s ability to maintain compliance with the Nasdaq minimum bid price requirement, or the other Nasdaq listing requirements; Evoke’s ability to obtain additional financing as needed to support its operations; the COVID-19 pandemic may continue to disrupt Evoke’s business operations impairing the ability to commercialize GIMOTI and Evoke’s ability to generate any product revenue; Evoke is entirely dependent on the success of GIMOTI; and other risks and uncertainties detailed in Evoke’s prior press releases and in the periodic reports it files with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Evoke undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.


 


 

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

June 8, 2022

 

EVOKE PHARMA, INC.

 

 

 

 

 

 

 

By:  /s/ Matthew J. D’Onofrio          

 

 

        Matthew J. D’Onofrio

    

 

        Executive Vice President,

 

 

        Chief Business Officer and Secretary

 

 

 

 

 

 

 

EX-101.SCH 2 evok-20220607.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000 - Document - Template Link link:presentationLink link:calculationLink link:definitionLink 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 3 evok-20220607_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Entity Central Index Key Cover [Abstract] Document Type Document Type Amendment Flag Amendment Flag Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Central Index Key Entity Emerging Growth Company Entity Emerging Growth Company Entity File Number Entity File Number Entity Incorporation, State or Country Code Entity Incorporation State Country Code Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address Address Line1 Entity Address, Address Line Two Entity Address Address Line2 Entity Address, City or Town Entity Address City Or Town Entity Address, State or Province Entity Address State Or Province Entity Address, Postal Zip Code Entity Address Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre-commencement Tender Offer Pre Commencement Tender Offer Pre-commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Title of 12(b) Security Security12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name EX-101.PRE 4 evok-20220607_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 5 R1.htm IDEA: XBRL DOCUMENT v3.22.1
Document and Entity Information
Jun. 07, 2022
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Jun. 07, 2022
Entity Registrant Name EVOKE PHARMA, INC.
Entity Central Index Key 0001403708
Entity Emerging Growth Company false
Entity File Number 001-36075
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 20-8447886
Entity Address, Address Line One 420 Stevens Avenue
Entity Address, Address Line Two Suite 370
Entity Address, City or Town Solana Beach
Entity Address, State or Province CA
Entity Address, Postal Zip Code 92075
City Area Code (858)
Local Phone Number 345-1494
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock,par value $0.0001 per share
Trading Symbol EVOK
Security Exchange Name NASDAQ
XML 6 evok-8k_20220607_htm.xml IDEA: XBRL DOCUMENT 0001403708 2022-06-07 2022-06-07 false 0001403708 8-K 2022-06-07 EVOKE PHARMA, INC. DE 001-36075 20-8447886 420 Stevens Avenue Suite 370 Solana Beach CA 92075 (858) 345-1494 Common Stock,par value $0.0001 per share EVOK NASDAQ false false false false false EXCEL 7 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 8 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 9 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 10 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.1 html 1 23 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.evokepharma.com/20220607/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports evok-8k_20220607.htm evok-20220607.xsd evok-20220607_lab.xml evok-20220607_pre.xml http://xbrl.sec.gov/dei/2022 true false JSON 12 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "evok-8k_20220607.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "evok-8k_20220607.htm" ] }, "labelLink": { "local": [ "evok-20220607_lab.xml" ] }, "presentationLink": { "local": [ "evok-20220607_pre.xml" ] }, "schema": { "local": [ "evok-20220607.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/currency/2022/currency-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd", "https://xbrl.sec.gov/exch/2022/exch-2022.xsd", "https://xbrl.sec.gov/naics/2022/naics-2022.xsd", "https://xbrl.sec.gov/sic/2022/sic-2022.xsd", "https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd" ] } }, "elementCount": 24, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 23, "memberCustom": 0, "memberStandard": 0, "nsprefix": "evok", "nsuri": "http://www.evokepharma.com/20220607", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "evok-8k_20220607.htm", "contextRef": "C_0001403708_20220607_20220607", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://www.evokepharma.com/20220607/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "evok-8k_20220607.htm", "contextRef": "C_0001403708_20220607_20220607", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.evokepharma.com/20220607/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.evokepharma.com/20220607/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.evokepharma.com/20220607/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.evokepharma.com/20220607/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address Address Line1", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.evokepharma.com/20220607/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address Address Line2", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.evokepharma.com/20220607/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address City Or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.evokepharma.com/20220607/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.evokepharma.com/20220607/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address State Or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.evokepharma.com/20220607/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.evokepharma.com/20220607/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.evokepharma.com/20220607/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.evokepharma.com/20220607/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.evokepharma.com/20220607/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.evokepharma.com/20220607/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.evokepharma.com/20220607/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.evokepharma.com/20220607/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.evokepharma.com/20220607/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.evokepharma.com/20220607/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security12b Title", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.evokepharma.com/20220607/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.evokepharma.com/20220607/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.evokepharma.com/20220607/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.evokepharma.com/20220607/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.evokepharma.com/20220607/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 13 0001564590-22-022768-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001564590-22-022768-xbrl.zip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